Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has provided an announcement.
Simcere Pharmaceutical Group has agreed to acquire the entire equity interest in a related diagnostics company for RMB30.76 million through an indirectly wholly owned subsidiary. After completion, the target will become an indirectly wholly owned subsidiary of Simcere, and its financial results will be consolidated into the group’s accounts, strengthening Simcere’s control over its diagnostics operations.
The deal is classified as a connected transaction under Hong Kong listing rules because the vendor is ultimately controlled by Simcere’s controlling shareholders, Mr. Ren Yong and Ms. Li Shimeng. As the applicable percentage ratio is above 0.1% but below 5%, the transaction requires public reporting and announcement but is exempt from independent shareholders’ approval, streamlining execution while still providing disclosure to investors.
The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company listed on the Stock Exchange of Hong Kong. The group operates through subsidiaries to develop and market pharmaceutical products, with a focus on expanding its portfolio and consolidating control over related medical and diagnostics businesses within its corporate structure.
Average Trading Volume: 6,403,851
Technical Sentiment Signal: Buy
Current Market Cap: HK$28.76B
For an in-depth examination of 2096 stock, go to TipRanks’ Overview page.